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Prognostic Significance of Peripheral T-Cell Subsets in Laryngeal
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Cesare Piazza, MD ; Giorgio Peretti, MD
Objectives: The role of the immune system in head and neck squamous cell carcinoma is controversial. The aim of our
study was to analyze full blood counts and distribution of T cell subsets in patients affected by laryngeal squamous cell cancer
(LSCC) and their association with clinical variables and survival.
Study design: Retrospective study.
Methods: We analyzed the levels of platelets, lymphocytes, and neutrophils, as well as the CD4+, CD8+, and CD3+ T-cell
subpopulations by cytofluorometry in LSCC patients. A cohort of healthy patients was used as control group. The disease-
specific survival (DSS) was considered as survival outcome.
Results: Sixty-five LSCC patients and 48 controls were enrolled. In LSCC patients, neutrophils were higher than in the
healthy group (P < .0001). The neutrophil-to-lymphocyte ratio (NLR) and the platelet-to-lymphocyte ratio (PLR) were both
higher in LSCC patients (P < .0001). In patients treated for recurrent disease, the CD8+/CD3+ ratio was increased (P = .02),
while the CD4+/CD8+ (P = .03) and CD4+/CD3+ (P = .04) ratios were lower. In patients with lymph node metastases, leukocytes
(P = .03), CD3+ (P = .04), and CD4+ (P = .0098) were all higher. Among Stages III-IV patients, low lymphocyte and low leuko-
cyte count were associated with worse DSS.
Conclusion: Our data demonstrate that NLR and PLR are significantly increased in LSCC. Lower CD4+/CD8+ and CD3+/CD8+
ratios are related to recurrent disease and a higher level of CD3+ and CD4+ is associated with nodal metastasis.
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INTRODUCTION
Laryngeal squamous cell cancer (LSCC) represents
one of the most common neoplasms among head and neck
squamous cell carcinomas (HNSCC) and it is one of a few
oncologic diseases in which the 5-year survival rate has
decreased over the past 40 years, from 66% to 63%, although
its overall incidence is declining.1,2 Carcinogenesis is a
multifactorial process that has not been fully elucidated, and
the role of immune system in the etiopathogenesis and pro-
gression of many cancers is a topic of paramount interest,
especially in recent years.3 Indeed, these aspects have
been thoroughly investigated in many types of solid
tumors, allowing a number of immunomodulatory and/or
immunostimulating drugs to be actively investigated in
clinical practice.4–8
The immune surveillance theory assigns specific roles
to different leukocyte populations: neutrophils, macro-
phages, and lymphocytes T-helper 2 (Th2) induce a cyto-
kine environment favoring chronic inflammation, typical of
neoplastic diseases, while natural killer cells, CD8+ lym-
phocytes, and major cytotoxic response factors comprise
tumor suppressor populations. However, despite extensive
research, reliable systemic inflammatory markers with
diagnostic and/or prognostic value are still lacking.
In recent years, there has been rising interest in the
use of systemic hematological markers as promising prog-
nosticators in malignancies. For instance, lymphocytopenia,
as well as thrombocytosis, have been associated with a
higher risk of development of colorectal cancer and mortal-
ity.9,10 The neutrophil-to-lymphocyte ratio (NLR) and
platelet-to-lymphocyte ratio (PLR), parameters derived from
routine pretreatment full blood count, have been recently
investigated in a variety of malignancies in which higher
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pretreatment ratios have been associated with worse prog-
nosis in terms of mortality and recurrence rates.11–13
To the best of our knowledge, few investigations have
considered this topic in the head and neck literature, with
particular emphasis on LSCC.14–20 Our study aimed to inves-
tigate how the immune system might change in patients
with LSCC compared to a control group of subjects treated
for a nonneoplastic, noninflammatory disease, and to investi-
gate a possible association with clinical-pathological charac-
teristics and prognosis.
MATERIALS AND METHODS
We enrolled 65 patients treated with curative intent for
primary or recurrent LSCC from March 2015 to June 2016 at
the Department of Otorhinolaryngology, Head and Neck Surgery,
University of Genoa, Italy. Ethical review and approval was not
required for this study in accordance with the national and insti-
tutional requirements; however, every patient preoperatively
signed a consent form for disclosure of privacy in managing per-
sonal data for scientific purposes in accordance with the Declara-
tion of Helsinki.
The only inclusion criterion was surgery with curative intent
for LSCC. Exclusion criteria were: known distant metastatic dis-
ease, previous cancers at other sites, immunological disorders, long-
term steroidal treatments, active concomitant infection or history of
chronic inflammatory conditions except for chronic obstructive pul-
monary disease, commonly observed in this patient population due
to widespread smoking; missing full blood tests or lymphocyte
counts. As a control group, we used a cohort of 48 subjects (40 males
and 8 females), matched for gender and age, undergoing surgery
for nasal septoplasty at the same Department.
The clinical and pathological variables analyzed were: age
at diagnosis, gender, smoking habit, status (i.e., first treatment
vs. recurrence), site (glottis vs. supraglottis), TNM classification
according to the 8th Edition,21 and grade. For survival analysis,
we considered the disease-specific survival (DSS), defined as the
time between the date of the surgery and the date of cancer
related death or last visit.
Routine full blood tests were obtained at pretreatment
workup for all patients (oncologic cohort and control group), and
the immunological parameters taken into account were the red
blood cells, white blood cells (WBCs), neutrophils, and lympho-
cyte counts. For the oncologic cohort, quantitative analysis of
CD3+, CD4+, and CD8+ T lymphocyte subpopulations was also
performed by cytofluorometry (FACS CANTO II Cytometer,
Becton Dickinson, San Jose, CA, USA).
The NLR was defined as the absolute neutrophil divided by
absolute lymphocyte counts.22 The PLR was considered as the
absolute platelet divided by absolute lymphocyte counts.14 We
also evaluated the CD4+/CD3+, CD8+/CD3+, and CD4+/CD8+
ratios defined as the ratios of the absolute counts of the respec-
tive T-cell subpopulations.
Statistical Analysis
Categorical data, including patient demographics (age, gen-
der, and smoking habit) and clinical-pathological characteristics
(status, site, T and N categories, staging, and grade) were dis-
played as frequency counts and percentages. Shapiro–Wilk test
of normality was applied to continuous variables (age, immuno-
logic cells counts, NLR, PLR, CD4+/CD3+, CD8+/CD3+, and CD4+/
CD8+ ratios). Subsequently, a nonparametric Mann–Whitney
test or Fisher’s exact test were chosen for group comparisons, as
appropriate. As an age of more than 60 years has been proved to
be an independent prognostic feature for DSS in HNSCC and
LSCC, we selected 60 years of age as the cutoff point.23 Univari-
ate survival analyses for DSS were calculated using the Kaplan–
Meier method and the differences in rates were assessed by log
rank test. The Cox proportional-hazards model was applied for
multivariable analysis. GraphPad Prism software Version 6.0
(San Diego, CA, USA) and R (version 3.3.1) were used for statisti-
cal analysis. In all tests, being tested two-sided, a P < .05 was
considered statistically significant.
RESULTS
Sixty-five patients (57 males, 8 females; mean age,
68 years; range, 41–83) treated with curative intent for
primary or recurrent LSCC were enrolled. Fifty-one
patients (78%) underwent transoral laser microsurgery,
11 (17%) total laryngectomy, and 3 (5%) open partial hori-
zontal laryngectomy; clinical and pathological features
are summarized in Table I. A control group, composed of
48 subjects (40 males and 8 females), matched for gender
and age, undergoing surgery for nasal septoplasty at the
same Department was identified.
The oncologic cohort of patients was comparable to
the control group according to age (P = .3), gender (P = .59)
and presence of comorbidities (P = .85; Table II). In
patients affected by LSCC, the total amounts of leucocytes
and neutrophils were significantly higher than in the con-
trol group (P = .001 and P < .0001, respectively). The NLR
and the PLR were also higher in LSCC patients compared
to the healthy group (P < .0001 and P < .0001, respec-
tively) (Table II and Fig. 1). Presence of comorbidities was
not associated neither with WBC (P = .95), neutrophils
(P = .80), lymphocytes (P = .91) or PLT counts (P = .06) nor
with NLR (P = .55) or PLR (P = .31).
TABLE I.
Patient Demographics and Clinical-Pathological Characteristics.
Variable n (%)
All 65 (100)
Age <60 15 (23)
≥60 50 (77)
Gender Female 8 (12)
Male 57 (88)
Smoke No 7 (11)
Yes 58 (89)
Status First treatment 52 (80)
Recurrence 13 (20)
Site Glottis 55 (85)
Supraglottis 10 (15)
T category T1-T2 39 (60)
T3-T4 26 (40)
N category N0 59 (91)
N+ 6 (9)
Stage I-II 38 (58)
III-IV 27 (42)
Grading G1 21 (32)
G2-G3 44 (68)
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Among the oncologic cohort, NLR was significantly
higher for the supraglottic than the glottic site
(P = .046), and PLR was higher in patients younger than
60 years compared to older ones (P = .04). In patients
treated for recurrent disease, compared to those previ-
ously untreated, the CD8+/CD3+ ratio was significantly
increased (P = .02), while the CD4+/CD8+ and CD4+/CD3+
ratios were lower (P = .03 and P = .04, respectively). In
patients with lymph node metastases, compared to those
without, a significant increase of the WBC (P = .02), CD3+
(P = .04), and CD4+ lymphocytes count (P = .01) was seen
(Table III).
Comparison between healthy subjects and LSCC
patients and within the oncologic cohort itself did not
reveal any other significant differences in the levels of
immune cells or their ratios (Tables II and III).
The mean DSS was 38.6 months (95% confidence inter-
val: 36.6–40.6); among the entire cohort 11 patients (17%)
developed recurrence during follow-up time, and 5 of them
died for disease progression. As all events of death related
to the disease were observed among patients in Stages III-
IV, further survival analysis was performed in this sub-
group. Among preoperative full blood results, for each con-
tinuous variable, the median value was chosen as the
cutoff. Low leukocyte and low lymphocyte counts were asso-
ciated with worse DSS (P = .02 and P = .003, respectively)
(Table IV and Fig. 2); among clinical data, only the presence
of risk factors (perineural invasion and/or lymphovascular
invasion) was related with a worse prognosis (P = .045). No
TABLE II.
Comparison of Full Blood Count Parameters in Oncologic Patients
and Healthy Controls.
Variables Patients N 65 Controls N 48 P
Age (years) 71 (61–77) 68 (63–73) .30*
Gender (Male) [N (%)] 57 (88%) 40 (83%) .59†
Presence of comorbidities [N (%)] 38 (58%) 29 (60%) .85†
RBC (106/μL) 4.8 (4.6–5.1) 5 (4.65–5.2) .21*
PLT (103/μL) 216 (174–271) 216 (186–247) .88*
WBC (103/μL) 7.3 (5.8–8.5) 5.9 (5.2–7.23) .001*
Neutrophils (103/μL) 4.8 (3.7–5.9) 3.55 (2.8–4.44) <.0001*
Lymphocytes (103/μL) 1.63 (1.2–2) 1.79 (1.46–2.03) .11*
NLR 2.86 (2.04–4.21) 2.1 (1.64–2.52) <.0001*
PLR 217 (175–272) 118 (98–142) <.0001*
Median values (I–III quartiles) reported.
*P values by Mann–Whitney test.
†P values by Fisher’s exact test.
RBC = red blood cell; PLT = platelets; WBC = white blood cell.
P
P P
P
Fig. 1. Comparison of full blood count parameters in oncologic patients and healthy controls. NLR = neutrophil to lymphocyte ratio;
PLR = platelet to lymphocyte ratio.
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other significant prognostic variable, among clinical data or
blood exams, was found (Table IV). The multivariable anal-
ysis confirmed the significantly independent adverse prog-
nostic value of having lower WBC count for DSS (hazard
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. TABLE IV.
Univariate Disease-Specific Survival among Stages III-IV Patients.
N (%)
Disease-Specific Survival
2-y Survival Probability P
Age ≥ 60 No 6 (22) 83% .78
Yes 21 (78) 82%
Gender Female 4 (15) 67% .54
Male 23 (85) 85%
Status Primary 22 (81) 84% .81
Recurrence 5 (19) 75%
Type treatment TLM 15 (56) 83% .73
Open neck 12 (44) 82%
Site GL 19 (70) 87% .53
SGL 8 (30) 71%
T category T2-T3 20 (74) 83% .69
T4a 7 (26) 83%
N status N0 21 (78) 80% .87
N+ 6 (22) 83%
Risk factors No 12 (44) 100% .045
Yes 15 (56) 71%
PLT Low 13 (48) 84% .93
High 14 (52) 82%
WBC Low 13 (48) 68% .02
High 14 (52) 100%
Neutrophils Low 12 (44) 74% .16
High 15 (56) 92%
Lymphocytes Low 13 (48) 58% .003
High 14 (52) 100%
NLR Low 13 (48) 83% .74
High 14 (52) 82%
PLR Low 13 (48) 84% .93
High 14 (52) 82%
CD3 Low 13 (48) 72% .12
High 14 (52) 92%
CD4 Low 13 (48) 69% .07
High 14 (52) 93%
CD8 Low 13 (48) 72% .12
High 14 (52) 92%
CD4/CD8 Low 13 (48) 74% .50
High 14 (52) 91%
CD4/CD3 Low 13 (48) 74% .50
High 14 (52) 91%
CD8/CD3 Low 13 (48) 90% .66
High 14 (52) 76%
Median values, used as cutoff for high or low levels of each variable,
were: PLT 222; WBC 8.00; Neutrophils 4.80; Lymphocytes 1.63; NLR 2.42;
PLR 224; CD3 1.35; CD4 0.74; CD8 0.49; CD4/CD8 1.94; CD4/CD3 0.66;
CD8/CD3 0.32. P values by log-rank test.
NLR = neutrophil-to-lymphocyte ratio; PLR = platelet-to-lymphocyte
ratio; PLT = platelets; Risk factors = perineural invasion and/or
lymphovascular invasion; WBC = white blood cells.
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ratio 0.419, P = .045; Table V), adjusted by lymphocyte
count and recurrent disease as a clinically relevant variable.
DISCUSSION
Already in the nineteenth century, Rudolf Virchow
underlined the intimate relationships between inflamma-
tion and malignancy based on the presence of leukocytes
in neoplastic tissues, while only 30 years ago Dvorak
showed how wound healing and tumor stroma formation
are linked by many important properties.24,25 Moreover,
malignant cells themselves secrete proinflammatory cyto-
kines. For all these reasons, the persistence of a noxious
stimulus induces the presence of lymphocytes, macro-
phages, and neutrophils in that tissue.26
Chronic inflammation secondary to different causes has
been associated with one-third of all tumors. The tumor itself
maintains chronic inflammation, leading to the production of
interleukins 4 and 5 (IL 4 and 5) and cytokines associatedwith
Th2 cells, whereas interferon gamma is associated with Th1
responses. Regarding inflammation, tumors represent a para-
dox: they produce inflammatory cytokines and chemokines,
but are infiltrated by leukocytes.27 However, these are associ-
ated with a poor capacity to initiate inflammatory reactions at
sites other than tumors, and circulating monocytes from can-
cer patients are notably defective in their ability to respond to
cytokines.
Several studies have linked oncological outcomes with
circulating neutrophils in a wide variety of tumors.28–30 In
the last decade, a rising number of authors reported the
role of both peripheral blood and tumor infiltration neu-
trophils or lymphocytes in HNSCC,31 with an even more
prominent role given to the NLR.13,15,32–34 HNSCCs
include a vast variety of tumors in terms of biological
behavior and histologies, and not discerning among that
multitude may lead to a mixture of results that cause
the inherent heterogeneity observed in various subsites
in terms of etiologies and survival rates.
Different studies have recently demonstrated that
the robust infiltration of HNSCC by CD3+ and CD8+
T cells is a favorable prognostic factor.35 Wolf et al. car-
ried out an elegant study on 40 patients affected by
HNSCCs: the patterns and degrees of lymphocyte subpop-
ulation infiltration in tumor parenchyma and stroma did
not differ by tumor site, except for LSCC.36 Kum et al.
have also shown that NLR may be a useful marker to dif-
ferentiate SCC patients from those with benign or pre-
cancerous lesions, as it is increased in the former.37 Wong
et al.38 also showed that patients with Stages III-IV
LSCC have a higher NLR than those with Stages I-II
lesions. Moreover, the prognostic significance of NLR in
terms of both overall survival and progression-free sur-
vival was also confirmed by multivariate analysis in a
large cohort of 654 patients treated for LSCC.18
Another study evaluated the role of systemic and
local inflammation in predicting outcomes in patients
with LSCC, finding that markers of systemic and local
inflammation, especially PLR and tumor infiltrating lym-
phocyte density, are reliable prognostic factors.39 The
PLR, also correlated with inflammation and malnutrition,
has been associated with poorer cancer-specific survival
at both univariate and multivariate analysis in a large
cohort (n = 899) by Mao et al.17 Starska et al. studied the
function of peripheral CD4+ and CD8+ T cells in LSCC,
finding an association between high local stage and the
presence of early activation antigens on these cells.19,20
However, the NLR, PLR, and the simultaneous anal-
ysis of the subpopulations of CD3+, CD4+, and CD8+
T cells in peripheral blood samples have never been pre-
viously investigated in LSCC, in particular discerning dif-
ferent lymphocyte subgroups in primary or recurrent
P P P
Fig. 2. Disease-specific survival (DSS) estimates (Kaplan–Meier) according to leukocyte (white blood cell), lymphocyte, and CD4+ T cell
counts.
TABLE V.
Multivariable Analysis for Disease-Specific Survival among Stages
III-IV Patients.
B P HR HR (95% CI)
WBC −0.869 .045 0.419 0.42 (0.18–0.98)
Lymphocytes −1.832 .16 0.16 0.16 (0.01–2.07)
Status (recurrent) 2.597 .119 13.419 13.42 (0.51–352.33)
B = ß coefficients; CI = confidence interval; HR = hazard ratio;
WBC = white blood cell.
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LSCC. The known bias considering also previously
treated patients, enrolled at the time of salvage surgery,
was managed including such variable in all analysis and
being the investigation of peripheral blood population
changes in those patients one of the main objectives of
the study. Our results confirm that the levels of circulat-
ing leukocytes and neutrophils are higher in LSCC
patients compared to healthy subjects. The result about
the worse prognostic value of a low level of leukocyte
count, also confirmed by the multivariable analysis, is in
agreement with the study of Hsueh et al. on a huge cohort
of 979 patients affected by LSCC that demonstrated its
independent prognostic significance for DSS at multivari-
ate analysis too.16 Moreover, since the CD8+/CD3+, the
CD4+/CD3+, and the CD4+/CD8+ ratios are significantly
different in patients treated for recurrence compared to
untreated ones, we propose to integrate these easy and
reproducible tools in the follow-up of previously treated
LSCC patients, as previously it has also been shown a
decreasing of lymphocyte count at the time of recurrence
in patients treated for head and neck cancer.40
In our series, as previously observed by Drennan
et al. in 2013 for laryngeal and oropharyngeal cancers,
the levels of CD3+ and CD4+ are higher in patients with
positive nodes than in those presenting an N0 neck.41
This finding could be explained by the inflammatory reac-
tion developing in the presence of lymph node metastasis
and advanced stages of disease. On the other hand,
González et al. found an opposite relationship, but in
their study only the relative frequencies of T cell subsets
were considered instead of their absolute counts.42 In
fact, it is well known that patients with more advanced
disease have significant systemic immunological changes,
including decreased numbers in activated dendritic cells,
an increase in regulatory T cells, depletion in PD-1
expressing T cells, and poor T cell function.43
CONCLUSION
In conclusion, while other HNSCCs have been investi-
gated more thoroughly, information on systemic inflamma-
tory markers and peripheral T cell subsets is lacking in
LSCC. Our preliminary study demonstrates that signifi-
cant changes in the peripheral immune system could have
a role in the development of LSCC or either could be a sys-
temic effect of it. Among patients affected by advanced
stages LSCC (Stage III-IV), the preoperative leukocyte
and lymphocyte counts, for their low cost and most of the
cases available yet, could be interesting biomarkers for
DSS to be further validated in wider analysis.
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